<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="111029">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02002065</url>
  </required_header>
  <id_info>
    <org_study_id>PRO-HA-4013 version 2.0</org_study_id>
    <nct_id>NCT02002065</nct_id>
  </id_info>
  <brief_title>The Fifth-year Follow-up Study for the Phase IV Clinical Trial of Hepatitis A Vaccine in Healthy Children</brief_title>
  <official_title>The Phase IV, Open-labelled, Follow-up Study to Evaluate the Five-year Immune Persistence of One Injection of Inactivated or Attenuated Alive Hepatitis A Vaccine in Healthy Chinese Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sinovac Biotech Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sinovac Biotech Co., Ltd</source>
  <oversight_info>
    <authority>China: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this follow-up study is to evaluate the five-year immune persistence of one
      injection of inactivated and attenuated alive hepatitis A vaccine in healthy children.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In the previous double-blind, randomized, phase IV clinical trial in 2008, 300 healthy
      Chinese children aged 18 to 35 months old were administered with one dose of  inactivated
      and attenuated alive hepatitis A vaccine. Series of serum samples were taken for
      immunogenicity and immune persistence evaluation. Safety observations were performed after
      vaccination. This trial was also approved by Tianjin CDC Biomedical Ethics Committee in
      2008.

      This study is the fifth-year follow-up research for the previous clinical trial.
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Anticipated">July 2014</completion_date>
  <primary_completion_date type="Anticipated">March 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>The geometric mean concentration (GMC) of anti-hepatitis A virus (HAV) antibodies in serum 60 months after vaccination</measure>
    <time_frame>60 months after vaccination</time_frame>
    <safety_issue>No</safety_issue>
    <description>to evaluate the immune persistence of anti-HAV antibodies in serum</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">300</enrollment>
  <condition>Hepatitis A</condition>
  <arm_group>
    <arm_group_label>Inactivated HAV vaccine</arm_group_label>
    <description>Inactivated vaccine: 0.5 ml per dose containing 250 u antigen, one dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Attenuated alive HAV vaccine</arm_group_label>
    <description>Attenuated alive vaccine: 1.0 ml per dose containing 6.50 lgCCID50 alive virus, one dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Inactivated HAV vaccine</intervention_name>
    <description>Inactivated vaccine: 0.5 ml per dose containing 250 u antigen, one dose</description>
    <arm_group_label>Inactivated HAV vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Attenuated alive HAV vaccine</intervention_name>
    <description>Attenuated alive vaccine: 1.0 ml per dose containing 6.50 lgCCID50 alive virus, one dose</description>
    <arm_group_label>Attenuated alive HAV vaccine</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Serum samples were taken from subjects.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Healthy Chinese children aged 18 to 35 months old
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All subjects who received inactivated or attenuated alive HAV vaccine in the previous
             trial

        Exclusion Criteria:

          -  Subjects who refused to continue in the follow-up study
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Months</minimum_age>
    <maximum_age>35 Months</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhi-Lun Zhang</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tianjin Center for Diseases Control and Prevention</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Tianjin center for disease prevention and control</name>
      <address>
        <city>Tianjin</city>
        <zip>300000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <lastchanged_date>December 4, 2013</lastchanged_date>
  <firstreceived_date>November 28, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>hepatitis A</keyword>
  <keyword>inactivated hepatitis A vaccine</keyword>
  <keyword>attenuated alive hepatitis A vaccine</keyword>
  <keyword>immune persistence</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
